<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41032430</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1853-0605</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)</Title><ISOAbbreviation>Rev Fac Cien Med Univ Nac Cordoba</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>484</StartPage><EndPage>504</EndPage><MedlinePgn>484-504</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31053/1853.0605.v82.n3.46375</ELocationID><Abstract><AbstractText>Introducci&#xf3;n: La cirrosis hep&#xe1;tica constituye un problema de salud p&#xfa;blica global, incrementando el riesgo de carcinoma hepatocelular(CHC), un c&#xe1;ncer altamente agresivo. El diagn&#xf3;stico temprano mediante estudios de im&#xe1;genes es crucial para un tratamiento oportuno. El objetivo fue describir las caracter&#xed;sticas cl&#xed;nicas y por im&#xe1;genes de pacientes con cirrosis y CHC en un hospital de tercer nivel de C&#xf3;rdoba, Argentina. Metodolog&#xed;a: Estudio anal&#xed;tico retrospectivo que revis&#xf3; historias cl&#xed;nicas de pacientes con cirrosis y/o CHC que se sometieron a tomograf&#xed;a computarizada(TC) y/o resonancia magn&#xe9;tica(RM) entre 2017 y 2023. Resultados: Se incluyeron 221 pacientes cirr&#xf3;ticos, 142(64,3%) varones, con una mediana: rango intercuartil 25-75%(n=RIC) de edad de 60: 54-66 a&#xf1;os. Las etiolog&#xed;as fueron: alcoh&#xf3;lica(30,3%), esteatohepatitis no alcoh&#xf3;lica (NASH) (26,2%), hepatitis B(21,7%), hepatitis C (12,2%) y otras(9,5%). Se diagnostic&#xf3; CHC en 42(19%) pacientes. Se realiz&#xf3; TC a todos los pacientes y RM a 22(52,4%). Entre los pacientes con CHC, NASH fue la causa m&#xe1;s com&#xfa;n(38,1%). Los criterios LI-RADS clasificaron a 30(71,4%) pacientes como LI-RADS-5, mientras que 12(28,6%) progresaron desde categor&#xed;as m&#xe1;s bajas. Durante el seguimiento de 18 meses, 22(9,95%) pacientes cirr&#xf3;ticos fallecieron. Conclusiones: La cirrosis alcoh&#xf3;lica fue la principal causa, y el CHC se diagnostic&#xf3; en el 19% de los pacientes. Se realiz&#xf3; TC en todos los pacientes con CHC y RM en la mitad. Ambas modalidades demostraron caracter&#xed;sticas de CHC en m&#xe1;s del 95% de los casos. La mortalidad a los 18 meses fue del 9,95% en pacientes cirr&#xf3;ticos y del 16% en pacientes con CHC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hospital Privado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mui&#xf1;o</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital Privado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orozco</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Privado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Emanuel Jos&#xe9;</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Hospital Privado.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas cl&#xed;nicas y de imagen en pacientes con cirrosis y carcinoma hepatocelular en un hospital de tercer nivel de C&#xf3;rdoba.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Rev Fac Cien Med Univ Nac Cordoba</MedlineTA><NlmUniqueID>8303003</NlmUniqueID><ISSNLinking>0014-6722</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="Y">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41032430</ArticleId><ArticleId IdType="doi">10.31053/1853.0605.v82.n3.46375</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40925449</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Fatigue in patients with inflammatory bowel disease: A descriptive cross-sectional study.</ArticleTitle><Pagination><StartPage>502557</StartPage><MedlinePgn>502557</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2025.502557</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(25)00427-3</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify factors associated with the presence of fatigue in patients with inflammatory bowel disease.</AbstractText><AbstractText Label="PATIENTS AND METHOD" NlmCategory="METHODS">Prospective cross-sectional descriptive study conducted in a multidisciplinary centre for the treatment of immune-mediated inflammatory disease (IMID). Participants were patients diagnosed with inflammatory bowel diseases (IBD) under follow-up in an advanced practice nurse (APN) consultation. Sociodemographic and clinical variables, biochemical parameters, disease activity, quality of life, severity of fatigue, anxiety and depression were collected. A multivariate analysis was performed with logistic regression adjusted for sex and years of disease progression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 243 patients were included, 174 (71.6%) with Crohn's disease and 69 (28.4%) with ulcerative colitis; 73 (30.2%) reported fatigue. Patients with fatigue had a significantly lower quality of life EuroQol-5D-5L: 60.08 vs. 76.34, (P&lt;.001, 95%CI: 12.15-20.36) and IBDQ-9 57.53 vs. 76.54 (P&lt;.001, 95%CI: 15.35-22.67). The regression model adjusted for sex and years of disease included moderate disease activity (OR: 4.88, P&lt;.001, 95%CI: 2.13-11. 14), probable case of anxiety (OR: 2.16, P=.031, 95%CI: 0.78-4.34), probable case of depression (OR: 2.86, P=.004, 95%CI: 1.41-5.81).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Fatigue was significantly associated with poorer health-related quality of life in patients with moderate disease activity and those experiencing anxiety or depression. These findings highlight the necessity of a comprehensive approach that includes early detection of fatigue and associated psychosocial factors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez-Calleja</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Cauce</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Madrid, Espa&#xf1;a; Servicio de Gastroenterolog&#xed;a, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iborra Colomino</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Gastroenterolog&#xed;a, Hospital Universitario y Polit&#xe9;cnico La Fe, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villarrubia-Mart&#xed;n</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mench&#xe9;n</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Madrid, Espa&#xf1;a; Servicio de Gastroenterolog&#xed;a, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo-Rodr&#xed;guez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Madrid, Espa&#xf1;a; Departamento de Enfermer&#xed;a, Facultad de Enfermer&#xed;a, Fisioterapia y Podolog&#xed;a, Universidad Complutense de Madrid, Madrid, Espa&#xf1;a. Electronic address: carmen.lobo@salud.madrid.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Fatiga en pacientes con enfermedad inflamatoria intestinal: estudio descriptivo transversal.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enfermedad Inflamatoria Inmuno-mediada</Keyword><Keyword MajorTopicYN="N">Enfermedad inflamatoria intestinal</Keyword><Keyword MajorTopicYN="N">Enfermeras cl&#xed;nicas</Keyword><Keyword MajorTopicYN="N">Fatiga</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Immune-mediated inflammatory disease (IMID)</Keyword><Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword><Keyword MajorTopicYN="N">Nurse clinicians</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40925449</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2025.502557</ArticleId><ArticleId IdType="pii">S0210-5705(25)00427-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40865109</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>Prevalence and characterization of human immunodeficiency virus coinfection in patients hospitalized with tuberculosis in a reference hospital in Bogot&#xe1;.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>435</EndPage><MedlinePgn>423-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.7664</ELocationID><Abstract><AbstractText>Introducci&#xf3;n. La tuberculosis es la principal causa de muerte en los pacientes con infecci&#xf3;n por el virus de la inmunodeficiencia humana. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es muy frecuente. Objetivo. Establecer la prevalencia de la infecci&#xf3;n por HIV en pacientes hospitalizados con tuberculosis, y determinar sus caracter&#xed;sticas y desenlaces. Materiales y m&#xe9;todos. Se realiz&#xf3; un estudio retrospectivo, de corte transversal, en pacientes con tuberculosis -pulmonar o extrapulmonar- y coinfecci&#xf3;n por HIV, hospitalizados en una instituci&#xf3;n de referencia de Bogot&#xe1; entre el 2019 y el 2021. Resultados. En el grupo de los 102 pacientes con tuberculosis, la prevalencia de infecci&#xf3;n por HIV fue del 52,3% (54). Entre estos 54, 24 pacientes (44,4%) tuvieron confirmaci&#xf3;n microbiol&#xf3;gica o histopatol&#xf3;gica de la tuberculosis y, 19 (35,2 %), infecci&#xf3;n por VIH de novo. En los 54 coinfectados, la mediana de la edad fue de 38 a&#xf1;os (RIC: 29-42). El 79,6 % (43/54) fueron hombres. La mediana del n&#xfa;mero de linfocitos T CD4+ fue de 59 c&#xe9;lulas/&#x3bc;l (RIC: 32-120), y el 72,2 % (39/54) ten&#xed;a menos de 200 c&#xe9;lulas/&#x3bc;l. El 31,4 % (17/54) de los pacientes con antecedente de infecci&#xf3;n por HIV recib&#xed;a terapia antirretroviral. En cuanto a la forma cl&#xed;nica, la tuberculosis fue pulmonar en el 51,9 % (28/54) y extrapulmonar en el 48,1 % (26/54) de los pacientes. La tuberculosis extrapulmonar fue men&#xed;ngea (29,6 %), miliar (12,9 %), pleural (3,7 %) y peritoneal (3,7 %). Hubo 33,3 % de mortalidad intrahospitalaria, asociada con el n&#xfa;mero de linfocitos T CD4+ (p &lt; 0,05), el diagn&#xf3;stico de novo de HIV (p &lt; 0,04) y la presencia de tuberculosis men&#xed;ngea (p &lt; 0,03). Conclusi&#xf3;n. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es frecuente y se relaciona con una inmunosupresi&#xf3;n avanzada, por lo que debe hacerse una b&#xfa;squeda activa de la infecci&#xf3;n con HIV en estos casos. La tuberculosis men&#xed;ngea fue la forma extrapulmonar m&#xe1;s frecuente y se asoci&#xf3; con mortalidad.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puentes-Ariza</LastName><ForeName>Gean Carlo</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0002-7001-1157</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mel&#xe9;ndez-Rhenals</LastName><ForeName>Sugeich</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4593-3125</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia; Servicio de Medicina Interna, Hospital Universitario Nacional de Colombia, Corporaci&#xf3;n Salud UN, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocua-B&#xe1;ez</LastName><ForeName>Laura Cristina</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0003-2869-2339</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;ez-Ardila</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4690-9055</Identifier><AffiliationInfo><Affiliation>Servicio de Infectolog&#xed;a, Hospital Sim&#xf3;n Bol&#xed;var, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prevalencia y caracterizaci&#xf3;n de la coinfecci&#xf3;n por el virus de la inmunodeficiencia humana en pacientes hospitalizados con tuberculosis en un hospital de referencia de Bogot&#xe1;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="INTRODUCTION.">Tuberculosis is the leading cause of death in patients with human immunodeficiency virus infection; tuberculosis-HIV coinfection is highly prevalent.</AbstractText><AbstractText Label="OBJECTIVE.">To establish the prevalence of HIV infection in patients hospitalized with tuberculosis and determine their characteristics and outcomes.</AbstractText><AbstractText Label="MATERIALS AND METHODS.">We conducted a retrospective cross-sectional study in patients diagnosed with pulmonary or extrapulmonary tuberculosis and HIV coinfection, hospitalized in a referral institution in Bogot&#xe1; between 2019 and 2021.</AbstractText><AbstractText Label="RESULTS.">The prevalence of HIV infection in 102 patients with tuberculosis was 52.3% (54/102). Among them, 24 patients (44.4%) had microbiological or histopathological confirmation of tuberculosis infection; and 19 (35.2%) were recently diagnosed with an HIV infection. The median age of the 54 coinfected patients was 38 years (IQR: 29-42); 79.6% (43/54) were men. The median CD4+ T-cell count was 59 cells/&#x3bc;L (IQR: 32-120), and 72.2% (39/54) had a CD4+ count of less than 200 cells/&#x3bc;L; 31.4% (17/54) of patients with a history of HIV infection were receiving antiretroviral therapy. Regarding tuberculosis clinical presentation, 51.9% (28/54) had pulmonary tuberculosis, and 48.1% (26/54) had extrapulmonary tuberculosis. The extrapulmonary tuberculosis forms were meningeal (29.6%), miliary (12.9%), pleural (3.7%), and peritoneal (3.7%). The in-hospital mortality was 33.3%, associated with a low CD4<sup>+</sup> count (p &lt; 0.05), recent HIV diagnosis (p &lt; 0.04), and the presence of meningeal tuberculosis (p &lt; 0.03).</AbstractText><AbstractText Label="CONCLUSION.">The frequency of tuberculosis-HIV coinfection is high and related to an advanced degree of immunosuppression. Therefore, we recommend an active search for coinfection. Meningeal tuberculosis was the most frequent extrapulmonary form and was associated with mortality.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">tuberculosis</Keyword><Keyword MajorTopicYN="N">pulmonary</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">opportunistic</Keyword><Keyword MajorTopicYN="N">infections</Keyword><Keyword MajorTopicYN="N">acquired</Keyword><Keyword MajorTopicYN="N">immunodeficiency</Keyword><Keyword MajorTopicYN="N">syndrome</Keyword></KeywordList><CoiStatement><b>Conflicto de intereses:</b> Los autores declaran no tener conflictos de intereses. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>20</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40865109</ArticleId><ArticleId IdType="pmc">PMC12448568</ArticleId><ArticleId IdType="doi">10.7705/biomedica.7664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(1005-70) doi: 10.1016/S0140-6736(14)60844-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60844-8</ArticleId><ArticleId IdType="pmc">PMC4202387</ArticleId><ArticleId IdType="pubmed">25059949</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(15035) doi: 10.1038/nrdp.2015.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.35</ArticleId><ArticleId IdType="pubmed">27188527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski A, Jansson M, Sk&#xf6;ld M, Rottenberg ME, Kallenius G. Tuberculosis and HIV coinfection. PLoS Pathog. 2012;8(1002464) doi: 10.1371/joumal.ppat.1002464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/joumal.ppat.1002464</ArticleId><ArticleId IdType="pmc">PMC3280977</ArticleId><ArticleId IdType="pubmed">22363214</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)   Global tuberculosis report 2024. Geneva: World Health Organization; 2024.  [18 de febrero de 2025].  Disponible en:  https://iris. who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1
.</Citation></Reference><Reference><Citation>Letang E, Ellis J, Naidoo K, Casas EC, S&#xe1;nchez P, Hassan-Moosa R, et al. Tuberculosis- HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-out. Arch Bronconeumol. 2020;56:446&#x2013;454. doi: 10.1016/j.arbr.2019.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbr.2019.11.013</ArticleId><ArticleId IdType="pubmed">35373756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med. 2013;34:32&#x2013;43. doi: 10.1055/s-0032-1333469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1333469</ArticleId><ArticleId IdType="pubmed">23460004</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge CL, King EJ, Dolan K, McKee M. Prisoners co-infected with tuberculosis and HIV: A systematic review. J Int AIDS Soc. 2016;19:20960&#x2013;20960. doi: 10.7448/IAS.19.1.20960.</Citation><ArticleIdList><ArticleId IdType="doi">10.7448/IAS.19.1.20960</ArticleId><ArticleId IdType="pmc">PMC5112354</ArticleId><ArticleId IdType="pubmed">27852420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis coinfection. Nat Rev Microbiol. 2018;16:80&#x2013;90. doi: 10.1038/nrmicro.2017.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.128</ArticleId><ArticleId IdType="pubmed">29109555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2013;8:e82235. doi: 10.1371/journal.pone.0082235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082235</ArticleId><ArticleId IdType="pmc">PMC3885391</ArticleId><ArticleId IdType="pubmed">24416139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood N, Wilkinson RJ. Understanding and intervening in HIV-associated tuberculosis. Clin Med (Lond) 2015;15(Suppl.6):S43&#x2013;S49. doi: 10.7861/clinmedicine.15-6-s43.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.15-6-s43</ArticleId><ArticleId IdType="pubmed">26634681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadul-P&#xe9;rez S. Protocolo de Vigilancia de Tuberculosis.  [13de junio de 2024];Instituto Nacional de Salud. 2022 :1&#x2013;33. Disponible en:  https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Tuberculosis%202022.pdf
.</Citation></Reference><Reference><Citation>Pan American Health Organization  . Factsheet 2022: TB/HIV co-infection in the Americas. Washington D. C.: PAHO/WHO; 2022.  [18 de febrero de 2025].  Disponible en:  https://www.paho.org/sites/default/files/2023-08/2022-cde-factsheet-tb-HIV-americas.pdf
.</Citation></Reference><Reference><Citation>Ministerio de Salud y Protecci&#xf3;n Social  . Lineamiento t&#xe9;cnico operativo del Programa Nacional de Tuberculosis. Direcci&#xf3;n de Promoci&#xf3;n y Prevenci&#xf3;n. Subdirecci&#xf3;n de Enfermedades Transmisibles. Bogot&#xe1;; D.C.: 2020.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%20227%20de%202020.pdf 
.</Citation></Reference><Reference><Citation>StataCorp . Stata Statistical Software: Release 15. College Station. Texas: StataCorp; 2017.</Citation></Reference><Reference><Citation>Ministerio de Salud  . Resoluci&#xf3;n n&#xfa;mero 8430 de 1993 por la cual se establecen las normas cient&#xed;ficas, t&#xe9;cnicas y administrativas para la investigaci&#xf3;n en salud. 1993.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.pdf
.</Citation></Reference><Reference><Citation>Frieden TR, Harold Jaffe DW, Moran JS, Leahy MA, Martinroe JC, Spriggs SR, et al. Revised surveillance case definition for HIV Infection - United States, 2014. Vol. 63. MMWR Recomm Rep; 2014. pp. 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24717910</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)   In danger: UNAIDS Global AIDS Update 2022. Geneva: UNAIDS; 2022.  [13 de junio de 2024].  Disponible en:  https://www.unaids.org/sites/default/files/media asset/2022-global-aids-update en.pdf
.</Citation></Reference><Reference><Citation>Kawatsu L, Uchimura K, Kaneko N, Imahashi M. Epidemiology of coinfection with tuberculosis and HIV in Japan, 2012-2020. West Pac Surveill Response J. 2022;13:1&#x2013;8. doi: 10.5365/wpsar.2022.13.1.896.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2022.13.1.896</ArticleId><ArticleId IdType="pmc">PMC9016268</ArticleId><ArticleId IdType="pubmed">35494412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar M, Moshe L, Daniel C, Noa C, Itamar G. HIV prevalence in the Israeli tuberculosis cohort, 1999-2011. BMC Public Health. 2014;14:1090&#x2013;1090. doi: 10.1186/1471-2458-14-1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-1090</ArticleId><ArticleId IdType="pmc">PMC4221682</ArticleId><ArticleId IdType="pubmed">25335562</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Regional Office for Europe, European Centre for Disease Prevention and Control  . HIV/AIDS surveillance in Europe 2024-2023 data. Copenhagen: WHO Regional Office for Europe; 2024.  [18 de febrero de 2025].  Disponible en:  https://www.ecdc.europa.eu/sites/default/files/documents/HIV_Surveillance_Report_2024.pdf
.</Citation></Reference><Reference><Citation>Cuenta de Alto Costo (CAC)   Situaci&#xf3;n del HIV en Colombia 2024. Bogot&#xe1;, D. C.: Fondo Colombiano de Enfermedades de Alto Costo; 2025.  [18 de febrero de 2025].  Disponible en:  https://cuentadealtocosto.org/publicaciones/situacion-del-HIV-en-colombia-2024/
</Citation></Reference><Reference><Citation>Cort&#xe9;s JA, Hidalgo P, Rey DL, Parra GA, Guti&#xe9;rrez IF. Tuberculosis en pacientes con infecci&#xf3;n por VIH en el Hospital Universitario de San Ignacio, 2002-2006. Infectio. 2007;11:16&#x2013;22.</Citation></Reference><Reference><Citation>Ruiz L, Maya MA, Rueda ZV, L&#xf3;pez L, V&#xe9;lez LA. Current characteristics of tuberculosis and human immunodeficiency virus co-infection in a cohort of hospitalized patients in Medell&#xed;n, Colombia. Biom&#xe9;dica. 2018;38:59&#x2013;67. doi: 10.7705/biomedica.v38i3.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3862</ArticleId><ArticleId IdType="pubmed">30184364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi MV, Sakabe S, Waldman EA. Mortality and survival of tuberculosis coinfected patients living with AIDS in S&#xe3;o Paulo, Brazil: A 12-year cohort study. BMC Infect Dis. 2022;22:223&#x2013;223. doi: 10.1186/s12879-022-07232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07232-6</ArticleId><ArticleId IdType="pmc">PMC8897065</ArticleId><ArticleId IdType="pubmed">35246066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanhueza-Sanzana C, Kerr L, Kendall C. Mortality from AIDS and tuberculosis- HIV coinfection in the Chilean AIDS Cohort of 2000-2017. Cad Sa&#xfa;de P&#xfa;blica. 2021;37:e00212920. doi: 10.1590/0102-311X00212920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-311X00212920</ArticleId><ArticleId IdType="pubmed">34190832</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a I, Merch&#xe1;n A, Chaparro PE, L&#xf3;pez LE. Panorama de la coinfecci&#xf3;n tuberculosis/HIV en Bogot&#xe1;, 2001. Biom&#xe9;dica. 2004;24(Supl.1):132&#x2013;137. doi: 10.7705/biomedica.v24iSupp1.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v24iSupp1.1312</ArticleId><ArticleId IdType="pubmed">15495581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont&#xfa;far Andrade FE, Villa Franco P, Mont&#xfa;far Pantoja MC, Zuleta Tob&#xf3;n JJ, P&#xe9;rez Jaramillo LE, Monsalve Valencia MA, et al. Coinfecci&#xf3;n por virus de inmunodeficiencia humana y micobacterias en un hospital universitario de alta complejidad en Colombia. Infectio. 2016;20:158&#x2013;164. doi: 10.1016/j.infect.2015.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infect.2015.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)  Global HIV &amp; AIDS statistics - Fact sheet 2024. Geneva: UNAIDS; 2024.  [19 de febrero de 2025].  Disponible en:   https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf 
.</Citation></Reference><Reference><Citation>de Vries G, van de Berg S, van Dam A, Hasanova S, Pareek M, van der Werf MJ, et al. Collaborative tuberculosis/HIV activities in the European Region. ERJ Open Res. 2021;7:00721&#x2013;02020. doi: 10.1183/23120541.00721-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00721-2020</ArticleId><ArticleId IdType="pmc">PMC7836583</ArticleId><ArticleId IdType="pubmed">33532469</ArticleId></ArticleIdList></Reference><Reference><Citation>Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, et al. The Effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: A systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2015;14:560&#x2013;570. doi: 10.1177/2325957415599210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325957415599210</ArticleId><ArticleId IdType="pubmed">26289343</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata-Casas L, Guti&#xe9;rrez-Lesmes O, Herr&#xe1;n-Falla O. Infecci&#xf3;n concomitante por tuberculosis y el virus de la inmunodeficiencia humana: situaci&#xf3;n epidemiol&#xf3;gica en el departamento del Meta, 2010-2015. Biom&#xe9;dica. 2018;38:68&#x2013;79. doi: 10.7705/biomedica.v38i3.3930.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3930</ArticleId><ArticleId IdType="pubmed">30184365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rindi L. Rapid molecular diagnosis of extra-pulmonary tuberculosis by Xpert/RIF ultra. Front Microbiol. 2022;13:817661&#x2013;817661. doi: 10.3389/fmicb.2022.817661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.817661</ArticleId><ArticleId IdType="pmc">PMC9130774</ArticleId><ArticleId IdType="pubmed">35633667</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. Tuberculous Meningitis International Research Consortium. The current global situation for tuberculous meningitis: Epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019;4:167&#x2013;167. doi: 10.12688/wellcomeopenres.15535.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15535.1</ArticleId><ArticleId IdType="pmc">PMC7029758</ArticleId><ArticleId IdType="pubmed">32118118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, P&#xe9;rez M, et al. Tuberculous meningitis in HIV-infected and non-infected patients: Comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis. 2009;13:269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40657777</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>168, abr.- jun.</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>44</EndPage><MedlinePgn>39-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53680/vertex.v36i168.833</ELocationID><Abstract><AbstractText>Introducci&#xf3;n: la categor&#xed;a de los Trastornos neurocognitivos (TNC), tambi&#xe9;n llamados Demencias, incluye a aquellos trastornos en los que el d&#xe9;ficit cl&#xed;nico principal es la falla en una o m&#xe1;s funciones cognitivas y que son adquiridos. La Demencia de Inicio Temprano (DIT) se define como un TNC mayor que comienza antes de los 65 a&#xf1;os, con diversas causas etiol&#xf3;gicas y un impacto significativo en los costos de salud y calidad de vida familiar. Los s&#xed;ntomas neuropsiqui&#xe1;tricos, como la depresi&#xf3;n y la ansiedad, pueden ser causas no neurodegenerativas de deterioro y quejas cognitivas. Este estudio se enfoca en describir el rendimiento en la Evaluaci&#xf3;n Neurocognitiva (ENC) y la presencia de depresi&#xf3;n, ansiedad, y otros s&#xed;ntomas neuropsiqui&#xe1;tricos en j&#xf3;venes que consultan por quejas cognitivas en un servicio de neurolog&#xed;a. Materiales y m&#xe9;todos: estudio descriptivo, retrospectivo basado en informes de ENC de pacientes j&#xf3;venes (&#x2264;64 a&#xf1;os) que consultaron por quejas cognitivas entre junio de 2018 y diciembre de 2022. Se excluyeron pacientes con antecedentes de trastornos del neurodesarrollo. Los informes clasificaron a los pacientes en categor&#xed;as basadas en su rendimiento cognitivo y la afectaci&#xf3;n en actividades de la vida diaria. Adem&#xe1;s, se recopilaron datos demogr&#xe1;ficos, antecedentes neurol&#xf3;gicos y psiqui&#xe1;tricos, y se utilizaron escalas para evaluar s&#xed;ntomas neuropsiqui&#xe1;tricos. Resultados: de las 214 ENC, 54.21 % resultaron normales, mientras que las restantes mostraron diversos grados de deterioro cognitivo. No se encontraron diferencias estad&#xed;sticamente significativas en la presencia de depresi&#xf3;n o ansiedad entre los grupos con ENC normal y patol&#xf3;gica. Sin embargo, el 84 % de los casos present&#xf3; s&#xed;ntomas neuropsiqui&#xe1;tricos seg&#xfa;n informes de familiares, siendo la depresi&#xf3;n y la ansiedad los m&#xe1;s reportados. Conclusiones: en m&#xe1;s de la mitad de la muestra se obtuvo un rendimiento cognitivo normal y en el resto alg&#xfa;n grado de deterioro cognitivo. Se detect&#xf3; una alta frecuencia de s&#xed;ntomas neuropsiqui&#xe1;tricos. Se subraya la importancia de una ENC completa y la detecci&#xf3;n de s&#xed;ntomas neuropsiqui&#xe1;tricos para una intervenci&#xf3;n temprana en pacientes j&#xf3;venes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deschle</LastName><ForeName>Florencia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>M&#xe9;dica especialista en Neurolog&#xed;a y en Neuropsicolog&#xed;a cl&#xed;nica. M&#xe9;dica de planta del Complejo m&#xe9;dico Hospitalario Churruca Visca. M&#xe9;dica de planta del Centro de Neurolog&#xed;a Cognitiva Hospital Brit&#xe1;nico de Buenos Aires. Buenos Aires, Argentina. florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caporale</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>M&#xe9;dica especialista en Neurolog&#xed;a. Jefa de residentes del Servicio de Neurolog&#xed;a del Complejo m&#xe9;dico Hospitalario Churruca Visca. Buenos Aires, Argentina. . florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Mar&#xed;a Cecilia</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Licenciada en Psicolog&#xed;a especialista en Neuropsicolog&#xed;a cl&#xed;nica. . florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervino</LastName><ForeName>Cecilia Ver&#xf3;nica</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Doctora en Psicolog&#xed;a especialista en Neuropsicolog&#xed;a cl&#xed;nica. Psic&#xf3;loga de planta del Complejo m&#xe9;dico Hospitalario Churruca Visca. Buenos Aires, Argentina. Neuropsic&#xf3;loga de planta Instituto FLENI.. florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saglio</LastName><ForeName>Mar&#xed;a Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Licenciada en Psicolog&#xed;a especialista en Neuropsicolog&#xed;a cl&#xed;nica. Psic&#xf3;loga de planta del Complejo m&#xe9;dico Hospitalario Churruca Visca. Neuropsic&#xf3;loga en Instituto de Investigaciones M&#xe9;dicas Lanari. Buenos Aires, Argentina. . florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>Guillermo Pablo</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>M&#xe9;dico especialista en Neurolog&#xed;a. Jefe del Servicio de Neurolog&#xed;a del Complejo M&#xe9;dico Hospitalario Churruca Visca. M&#xe9;dico de planta de Secci&#xf3;n Neurolog&#xed;a vascular del instituto FLENI. . florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berrios</LastName><ForeName>Waleska</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>M&#xe9;dica especialista en Neurolog&#xed;a. M&#xe9;dica de planta del Complejo m&#xe9;dico Hospitalario Churruca Visca. M&#xe9;dica asociada de la Secci&#xf3;n Trastornos de Memoria y Conducta del Hospital Italiano de Buenos Aires. Buenos Aires, Argentina.. florenciadeschle@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Poblaci&#xf3;n joven con queja cognitiva: performance neuropsicol&#xf3;gica y s&#xed;ntomas neuropsiqui&#xe1;tricos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="Y">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>8</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40657777</ArticleId><ArticleId IdType="doi">10.53680/vertex.v36i168.833</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40521691</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Association of Cumulative Social Risk and Cancer-Specific Survival Among Patients With Advanced Colorectal Cancer.</ArticleTitle><Pagination><StartPage>1085</StartPage><EndPage>1092</EndPage><MedlinePgn>1085-1092</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003851</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Socioeconomic disadvantage is widely associated with poor clinical outcomes among patients with colorectal cancer. Interventions to address these pervasive public health problems have had mixed success, potentially related to their development based on aggregated data (eg, average zip code income) and short-term outcomes, rather than individual-level data and meaningful long-term cancer outcomes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze associations of individual and cumulative multiple, co-occurring individual-level social risk factors with long-term cancer-specific survival among patients with advanced colorectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Between 2011 and 2014, we collaborated with Surveillance, Epidemiology and End Result in Georgia and Detroit to survey patients with stage III colorectal cancer in the prior year. Cumulative social risk was calculated by summing significant factors associated with colorectal cancer-specific mortality: employment, insurance, health literacy, income, and marital status.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with stage III colorectal cancer were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Time from diagnosis to cancer-specific mortality, adjusted for age, race, sex, and chemotherapy receipt, with comparisons provided in HRs with 95% CIs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1173 patients, preoperative unemployment (1.76 [1.30-2.39]), uninsured or Medicaid insurance (1.54 [1.12-2.11]), low health literacy (1.40 [1.00-1.95]), annual income below $50,000 (1.34 [1.01-1.77]), and being unpartnered (1.34 [1.02-1.77]) were associated with higher likelihood of cancer-specific mortality. In cumulative risk analyses, each added social risk was associated with a 24% higher adjusted likelihood of cancer-specific mortality (1.24 [1.12-1.37]).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study has limitations inherent to survey research, including the potential lack of generalizability and the possibility of responses being subject to recall bias. In addition, the cross-sectional survey and linked longitudinal clinical data do not allow for the determination of causality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cumulative social risk was associated with long-term cancer-specific survival after treatment for stage III colorectal cancer. Assessing social risk may help identify patients with colorectal cancer who are at higher risk of mortality to receive support programs designed to mitigate social disadvantage. See Video Abstract .</AbstractText><AbstractText Label="ASOCIACIN ENTRE EL RIESGO SOCIAL ACUMULADO Y LA SUPERVIVENCIA ESPECFICA POR CNCER EN PACIENTES CON CNCER COLORRECTAL AVANZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:Las desventajas socioecon&#xf3;micas se asocian ampliamente con malos resultados cl&#xed;nicos en pacientes con c&#xe1;ncer colorrectal. Las intervenciones para abordar estos problemas de salud p&#xfa;blica han tenido un &#xe9;xito desigual, lo que podr&#xed;a estar relacionado con su desarrollo basado en datos agregados (por ejemplo, los ingresos medios por c&#xf3;digo postal) y en resultados a corto plazo, en vez de en datos a nivel individual y en resultados significativos de c&#xe1;ncer a largo plazo.OBJETIVO:Examinar las asociaciones individuales y acumulativas entre los factores de riesgo social m&#xfa;ltiples concurrentes a nivel del individuo con la supervivencia a largo plazo espec&#xed;fica para c&#xe1;ncer entre pacientes con c&#xe1;ncer colorrectal avanzado.DISE&#xd1;O:Estudio prospectivo de cohortes.ENTORNO:Entre 2011 y 2014, colaboramos con Surveillance, Epidemiology and End Result en Georgia y Detroit para encuestar a pacientes con c&#xe1;ncer colorrectal en estadio III en el a&#xf1;o anterior. El riesgo social acumulativo se calcul&#xf3; sumando los factores significativos asociados con la mortalidad espec&#xed;fica por c&#xe1;ncer colorrectal: empleo, seguro m&#xe9;dico, conocimientos sobre salud, ingresos y estado civil.PACIENTES:Pacientes con c&#xe1;ncer colorrectal en estadio III.PRINCIPALES MEDIDAS DE RESULTADO:Tiempo transcurrido desde el diagn&#xf3;stico hasta la mortalidad espec&#xed;fica por c&#xe1;ncer, ajustado por edad, raza, sexo y recepci&#xf3;n de quimioterapia, con comparaciones proporcionadas en razones de riesgo con intervalos de confianza del 95 %.RESULTADOS:Entre los 1173 pacientes, el desempleo preoperatorio (1,76 [1,30-2,39]), la falta de seguro o el seguro Medicaid (1,54 [1,12-2,11]), los bajos conocimientos sobre salud (1,40 [1,00-1,95]), ingresos anuales &lt; 50 000 d&#xf3;lares (1,34 [1,01-1,77]) y no tener pareja (1,34 [1,02-1,77]) se asociaron con una mayor probabilidad de mortalidad espec&#xed;fica por c&#xe1;ncer. En los an&#xe1;lisis de riesgo acumulativo, cada riesgo social a&#xf1;adido se asoci&#xf3; con un 24 % m&#xe1;s de probabilidad ajustada de mortalidad espec&#xed;fica por c&#xe1;ncer (1,24 [1,12-1,37]).LIMITACIONES:Este estudio tiene limitaciones inherentes a la investigaci&#xf3;n mediante encuestas, incluida la posible falta de generalizaci&#xf3;n y las respuestas sujetas a sesgos de recuerdo. Adem&#xe1;s, la encuesta transversal y los datos cl&#xed;nicos longitudinales vinculados no permiten determinar la causalidad.CONCLUSI&#xd3;N:El riesgo social acumulado se asoci&#xf3; con la supervivencia a largo plazo espec&#xed;fica por c&#xe1;ncer despu&#xe9;s del tratamiento para el c&#xe1;ncer colorrectal en estadio III. La evaluaci&#xf3;n del riesgo social puede ayudar a identificar a los pacientes con c&#xe1;ncer colorrectal que tienen un mayor riesgo de mortalidad para que reciban programas de apoyo dise&#xf1;ados para mitigar las desventajas sociales. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yelorda</LastName><ForeName>Kirbi L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnow</LastName><ForeName>Katherine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Sue J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sanghyun A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-5795-2940</Identifier><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005845" MajorTopicYN="N" Type="Geographic">Georgia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer-specific</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Risk</Keyword><Keyword MajorTopicYN="N">Social determinants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40521691</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003851</ArticleId><ArticleId IdType="pii">00003453-990000000-00979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. Colorectal cancer statistics. Colorectal Cancer. https://www.cdc.gov/colorectal-cancer/statistics/index.html . Accessed March 13, 2025.</Citation></Reference><Reference><Citation>Social Determinants of Health - Healthy People 2030 | odphp.health.gov. https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health . Accessed February 16, 2025.</Citation></Reference><Reference><Citation>Coughlin SS. Social determinants of colorectal cancer risk, stage, and survival: a systematic review. Int J Colorectal Dis. 2020;35:985&#x2013;995.</Citation></Reference><Reference><Citation>Dawes AJ, Rajasekar G, Arnow KD, et al. Disparities in access, quality, and clinical outcome for latino Californians with colon cancer. Ann Surg. 2025;281:469&#x2013;475.</Citation></Reference><Reference><Citation>Morris AM, Billingsley KG, Baxter NN, Baldwin LM. Racial disparities in rectal cancer treatment: a population-based analysis. Arch Surg. 2004;139:151&#x2013;155.</Citation></Reference><Reference><Citation>Egeberg R, Halkjaer J, Rottmann N, Hansen L, Holten I. Social inequality and incidence of and survival from cancers of the colon and rectum in a population-based study in Denmark, 1994-2003. Eur J Cancer. 2008;44:1978&#x2013;1988.</Citation></Reference><Reference><Citation>Shaw C, Blakely T, Sarfati D, Fawcett J, Peace J. Trends in colorectal cancer mortality by ethnicity and socio-economic position in New Zealand, 1981-99: one country, many stories. Aust N Z J Public Health. 2006;30:64&#x2013;70.</Citation></Reference><Reference><Citation>Doria C, De Deyne PG, Charalampos P. Vulnerability in colorectal cancer: adjusted gross income and geography as factors in determining overall survival in colorectal cancer: a single-center study across a broad income inequality in an American context. Curr Oncol. 2024;31:7754&#x2013;7764.</Citation></Reference><Reference><Citation>Hussaini SMQ, Fan Q, Barrow LCJ, Yabroff KR, Pollack CE, Nogueira LM. Association of historical housing discrimination and colon cancer treatment and outcomes in the United States. JCO Oncol Pract. 2024;20:678&#x2013;687.</Citation></Reference><Reference><Citation>Kanters AE, Morris AM, Abrahamse PH, Mody L, Suwanabol PA. The effect of peer support on colorectal cancer patients&#x2019; adherence to guideline-concordant multidisciplinary care. Dis Colon Rectum. 2018;61:817&#x2013;823.</Citation></Reference><Reference><Citation>Healy MA, Morris AM, Abrahamse P, Ward KC, Kato I, Veenstra CM. The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer. 2018;18:481.</Citation></Reference><Reference><Citation>Davis RE, Trickey AW, Abrahamse P, Kato I, Ward K, Morris AM. Association of cumulative social risk and social support with receipt of chemotherapy among patients with advanced colorectal cancer. JAMA Netw Open. 2021;4:e2113533.</Citation></Reference><Reference><Citation>Veenstra CM, Regenbogen SE, Hawley ST, et al. A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care. 2014;52:957&#x2013;962.</Citation></Reference><Reference><Citation>Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36:588&#x2013;594.</Citation></Reference><Reference><Citation>Lawrence JA, Kawachi I, White K, et al. A systematic review and meta-analysis of the Everyday Discrimination Scale and biomarker outcomes. Psychoneuroendocrinology. 2022;142:105772.</Citation></Reference><Reference><Citation>Simmons LA, Modesitt SC, Brody AC, Leggin AB. Food insecurity among cancer patients in Kentucky: a pilot study. J Oncol Pract. 2006;2:274&#x2013;279.</Citation></Reference><Reference><Citation>Jayakrishnan TT, Bakalov V, Chahine Z, Finley GG, Monga DK, Wegner RE. How do social determinants of health impact timeliness of chemotherapy and survival in patients with metastatic colon cancer? A 12-year study. J Clin Oncol. 2020;38(suppl):36&#x2013;36.</Citation></Reference><Reference><Citation>Danos DM, Ferguson TF, Simonsen NR, et al. Neighborhood disadvantage and racial disparities in colorectal cancer incidence: a population-based study in Louisiana. Ann Epidemiol. 2018;28:316&#x2013;321.e2.</Citation></Reference><Reference><Citation>Haas JS, Earle CC, Orav JE, Brawarsky P, Neville BA, Williams DR. Racial segregation and disparities in cancer stage for seniors. J Gen Intern Med. 2008;23:699&#x2013;705.</Citation></Reference><Reference><Citation>Askari A, Nachiappan S, Currie A, et al. The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiol. 2017;47:88&#x2013;93.</Citation></Reference><Reference><Citation>Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy. CA Cancer J Clin. 2020;70:31&#x2013;46.</Citation></Reference><Reference><Citation>Hamity C, Jackson A, Peralta L, Bellows J. Perceptions and experience of patients, staff, and clinicians with social needs assessment. Perm J. 2018;22:18&#x2013;105.</Citation></Reference><Reference><Citation>ScienceDirect. Social support and outcomes in older adults with lung cancer. https://www-sciencedirect-com.laneproxy.stanford.edu/science/article/pii/S1879406821002101?via%3Dihub. Accessed March 17, 2025.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40511773</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1073</EndPage><MedlinePgn>1062-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Seventeen medical centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with IBD undergoing colectomy and/or proctectomy were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Chemoprophylaxis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thirty-day venous thromboembolism (clot) rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome ( p = 0.0005) and extended resections ( p &lt; 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively ( p &lt; 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge ( p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The limitations to this study were generalizability and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract .</AbstractText><AbstractText Label="PATRONES DE PRCTICA, RESULTADOS Y ESTRATIFICACIN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGA POR ENFERMEDAD INFLAMATORIA INTESTINAL ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRRGICA SOBRE EII" NlmCategory="UNASSIGNED">ANTECEDENTES:No se ha definido la estrategia &#xf3;ptima de quimioprofilaxis de la tromboembolia venosa tras la cirug&#xed;a por enfermedad inflamatoria intestinal.OBJETIVO:Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirug&#xed;a por enfermedad inflamatoria intestinal en una cohorte retrospectiva.DISE&#xd1;O:Entre julio de 2020 y octubre de 2023, la Colaboraci&#xf3;n sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica.ENTORNO:Diecisiete centros m&#xe9;dicos.PACIENTES:Pacientes con enfermedad inflamatoria intestinal sometidos a colectom&#xed;a y/o proctectom&#xed;a.INTERVENCIONES:Quimioprofilaxis.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de tromboembolia venosa (co&#xe1;gulos) a 30 d&#xed;as.RESULTADOS:Durante tres a&#xf1;os, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un co&#xe1;gulo en un plazo de 30 d&#xed;as: el 50 % antes y despu&#xe9;s del alta, respectivamente. Los co&#xe1;gulos se diagnosticaron una mediana de 9 d&#xed;as despu&#xe9;s de la operaci&#xf3;n. Los co&#xe1;gulos m&#xe1;s frecuentes fueron portomesent&#xe9;ricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utiliz&#xf3; una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorr&#xe1;gicas. El an&#xe1;lisis multivariable revel&#xf3; que el s&#xed;ndrome de respuesta inflamatoria sist&#xe9;mica preoperatoria ( p = 0.0005) y las resecciones extendidas ( p &lt; 0.0001) eran factores de riesgo independientes para los co&#xe1;gulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de co&#xe1;gulos del 1.2 %, 4.0 % y 13.5 %, respectivamente ( p &lt; 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoci&#xf3; de forma independiente con un menor riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta ( p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de co&#xe1;gulos del 2.5 %, el n&#xfa;mero estimado de pacientes que deb&#xed;an recibir tratamiento con enoxaparina durante la hospitalizaci&#xf3;n y despu&#xe9;s del alta fue de 54 y 55, respectivamente.LIMITACIONES:Generalizaci&#xf3;n; sesgo de selecci&#xf3;n.CONCLUSIONES:Tras la cirug&#xed;a por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoci&#xf3; con una disminuci&#xf3;n del riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta. Los pacientes con mayor riesgo pueden beneficiarse m&#xe1;s de una quimioprofilaxis prolongada. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-2549-9042</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2646-0625</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego School of Medicine, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0003-3418-6774</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Colorectal Surgery Program, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-9138-186</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla F</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-9526-0643</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0382-880</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8273-9471</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krane</LastName><ForeName>Mukta K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4872-1061</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Washington Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5814-3915</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-4010-5275</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Colectomy</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ileoanal pouch</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Proctectomy</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germaine</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavryk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narsule</LastName><ForeName>Chaitan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenkranz</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Valora</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511773</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003833</ArticleId><ArticleId IdType="pii">00003453-990000000-00977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation></Reference><Reference><Citation>GamalEldin M, DeHaan RK, Sklow B, et al. Portomesenteric venous thrombosis after colorectal surgery for inflammatory bowel disease: a call to action? [ASCRS abstract POD232]. Dis Colon Rectum. 2021;64:e109&#x2013;e364.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Cima RR, Habermann EB. Timing and location of venous thromboembolisms after surgery for inflammatory bowel disease. J Surg Res. 2024;296:563&#x2013;570.</Citation></Reference><Reference><Citation>Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138&#x2013;1144.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>Eisenstein S, Holubar SD, Hilbert N, et al. The ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: design, implementation, and validation of a disease-specific module. Inflamm Bowel Dis. 2019;25:1731&#x2013;1739.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a national surgical quality improvement program database study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do patients with inflammatory bowel disease have a higher postoperative risk of venous thromboembolism or do they undergo more high-risk operations? Ann Surg. 2020;271:325&#x2013;331.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304&#x2013;312.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632&#x2013;634.</Citation></Reference><Reference><Citation>Benlice C, Holubar SD, Gorgun E, et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum. 2018;61:1170&#x2013;1179.</Citation></Reference><Reference><Citation>Cheong JY, Connelly TM, Russell T, et al. Venous thromboembolism risk stratification for patients undergoing surgery for IBD using a novel six factor scoring system using NSQIP-IBD registry. ANZ J Surg. 2023;93:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433&#x2013;436.</Citation></Reference><Reference><Citation>Montero Ruiz E, Baldominos Utrilla G, L&#xf3;pez &#xc1;lvarez J, Santolaya Perrin R. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011;128:440&#x2013;445.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422&#x2013;1430.</Citation></Reference><Reference><Citation>Lee CHA, Jia X, Lipman JM, et al. Defining the economic burden of perioperative venous thromboembolism in inflammatory bowel disease in the United States. Dis Colon Rectum. 2021;64:871&#x2013;880.</Citation></Reference><Reference><Citation>Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn&#x2019;s disease. Dis Colon Rectum. 2019;62:1371&#x2013;1380.</Citation></Reference><Reference><Citation>Leeds IL, Haut ER. Are we really supposed to start giving venous thromboembolism prophylaxis for a month after outpatient surgery? JAMA Surg. 2019;154:1133.</Citation></Reference><Reference><Citation>Prien C, Ribakow D, Steele SR, et al. What about patient cost? Defining copay and out-of-pocket costs of extended venous thromboembolism chemoprophylaxis after colorectal surgery. J Gastrointest Surg. 2023;27:152&#x2013;154.</Citation></Reference><Reference><Citation>Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: a quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131&#x2013;139.</Citation></Reference><Reference><Citation>Ogilvie JW Jr, Khan MT, Hayakawa E, Parker J, Luchtefeld MA. Low-dose rivaroxaban as extended prophylaxis reduces postdischarge venous thromboembolism in patients with malignancy and IBD. Dis Colon Rectum. 2024;67:457&#x2013;465.</Citation></Reference><Reference><Citation>Holubar SD, Eisenstein S, Bordeianou L, et al. Venous thromboembolism prophylaxis practice patterns, outcomes, and risk stratification after surgery for inflammatory bowel disease: a NSQIP IBD Collaborative study. Dis Colon Rectum. 2025;68:e228&#x2013;e229.</Citation></Reference><Reference><Citation>Cordova-Cassia C, Wong D, Cotter MB, Cataldo TE, Poylin VY. Patient&#x2019;s compliance is a contributor to failure of extended antithrombotic prophylaxis in colorectal surgery: prospective cohort study. Surg Endosc. 2022;36:267&#x2013;273.</Citation></Reference><Reference><Citation>Elzaafarany A, Tawfik A, Igbekele T, Day A. EP-351 Extended VTE prophylaxis in patients undergoing elective surgery for colorectal cancer in a district general hospital and its compliance with NICE guidelines. Br J Surg. 2022;109(Suppl 5):znac245.091.</Citation></Reference><Reference><Citation>Yeung T, Ng S, Sidhu R, Ali M. 463 Adherence to extended venous thromboembolism prophylaxis for post operative resection of colorectal malignancies. Br J Surg. 2023;110(Suppl 7):znad258.105.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>